Empowering Leaders at the Global Pharma Executive Course: Navigating Industry Transformation

By João L. Carapinha

January 13, 2026

The fourth edition of the Global Pharma Executive Course runs from March to May 2026 at Portugal’s Faculdade de Medicina da Universidade Católica Portuguesa and Hospital da Luz Lisboa. The course targets pharma industry leaders, as rapid changes driven by tech advances, therapeutic innovation, and new market access models reshape the sector. The program offers practical, interactive training that covers key areas like R&D and supply chain, along with market access, business models, technology, future health trends, sustainability, and patient strategies. Renowned speakers from Pfizer and MSD join, as do those from Johnson & Johnson and Sanofi, while ViiV Healthcare, Roche, and Bluepharma participate too. GenH organizes it along with the Centro Académico Clínico Católica-Luz, fostering strategic leadership and networking as Portugal emerges as a European pharma hub.

The Global Pharma Executive Course stresses integrated leadership that bridges science, clinical practice, and industry, helping leaders navigate supply chain issues, handle digital innovation, and adopt patient-centric models. Portugal positions itself as a strategic player in European pharma education, where practical case studies and access from C-level executives at top firms highlight real-world skills. There’s value for professionals in health and pharma sciences, as well as management and law fields, while networks build around trends like sustainability and omnichannel strategies to stay ahead. After three editions, it has become a national reference that promotes competitiveness and improves long-term sector sustainability.

From a HEOR perspective, the program boosts leaders who integrate real-world evidence to aid market access and pricing, potentially leading to optimized value-based models and dropping drug lifecycle inefficiencies. Explore details at the Global Pharma Executive Course.

Reference url

Recent Posts

Catalyzing Cardiovascular Health Innovation through Urban Interventions and Collaborative Research

By HEOR Staff Writer

March 12, 2026

Cardiovascular health innovation is at the forefront of the Innovative Health Initiative (IHI), the world's largest public-private partnership in life sciences, which succeeds the Innovative Medicines Initiative (IMI). Key projects from IHI Call 8, such as Cities@Heart, target cardiovascular dise...
EMA Approval Submission for Teclistamab Multiple Myeloma Monotherapy
Johnson & Johnson has submitted a Type II variation application to the European Medicines Agenc...
European Cancer Care: Balancing Economic Stability with Improved Survival Rates
European Cancer Care has achieved substantial improvements in survival rates without a disproportionate escalation in health budgets, as evidenced by the